Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 12, 2014, Pages 1268-1272

  Hoffmann, Falk ^a   Glaeske, Gerd ^a   Bachmann, Christian J ^b  

^a UNIVERSITY OF BREMEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antidepressants; Children; Germany; Health services research; Outpatient; Pharmacoepidemiology

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; OPIPRAMOL; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GERMAN DEMOCRATIC REPUBLIC; GERMAN FEDERAL REPUBLIC; HEALTH INSURANCE; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTPATIENT; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; EPIDEMIOLOGY; GERMANY; HISTORY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HISTORY, 21ST CENTURY; HUMANS; LONGITUDINAL STUDIES; MALE; PRESCRIPTIONS; YOUNG ADULT;

EID: 84914177056     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3649     Document Type: Article

References (27)

1. Rapoport JL. Pediatric psychopharmacology: too much or too little? World Psychiat 2013; 12: 118-123. doi:10.1002/wps.20028.
2. Hoffmann F, Glaeske G, Petermann F, Bachmann CJ. Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. Pharmacoepidemiol Drug Saf 2012; 21: 972-979. doi:10.1002/pds.3295.
3. Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry 2013; 22: 511-518. doi:10.1007/s00787-013-0395-9.
4. Hoffmann F, Petermann F, Glaeske G, Bachmann CJ. Prevalence and comorbidities of adolescent depression in Germany. An analysis of Health Insurance Data. Z Kinder Jugendpsychiatr Psychother 2012; 40: 399-404. doi:10.1024/1422-4917/a000199.
5. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11: CD004851. doi:10.1002/14651858.CD004851.pub3.
6. Brent DA. Antidepressants and pediatric depression-the risk of doing nothing. N Engl J Med 2004; 351: 1598-1601. doi:10.1056/NEJMp048228.
7. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65: 94-101. doi:10.1001/archgenpsychiatry.2007.5.
8. Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006; 16: 197-206. doi:10.1089/cap.2006.16.197.
9. Hoffmann F, Icks A. Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor. Gesundheitswesen 2012; 74: 291-297. doi:10.1055/s-0031-1275711.
10. Hoffmann F, Icks A. Diabetes prevalence based on health insurance claims: large differences between companies. Diabet Med 2011; 28: 919-923. doi:10.1111/j.1464-5491.2011.03305.x.
11. Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 2013; 34: 2551-2563. doi:10.1016/j.ridd.2013.05.028.
12. Bachmann CJ, Lempp T, Glaeske G, Hoffmann F. Antipsychotic Prescription in Children and Adolescents: an Analysis of Data From a German Statutory Health Insurance Company From 2005 to 2012. Dtsch Arztebl Int 2014; 111: 25-34.
13. Barkmann C, Schulte-Markwort M. Prevalence of emotional and behavioural disorders in German children and adolescents: a meta-analysis. J Epidemiol Community Health 2012; 66: 194-203. doi:10.1136/jech.2009.102467.
14. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010; 49: 1001-1010. doi:10.1016/j.jaac.2010.07.007.
15. Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 2012; 7: e33181. doi:10.1371/journal.pone.0033181.
16. Steinhausen H-C, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 2014; 129: 221-231. doi:10.1111/acps.12155.
17. Zito JM, Tobi H, de Jong-van den Berg LTW, et al. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 2006; 15: 793-798. doi:10.1002/pds.1254.
18. Olfson M, He J-P, Merikangas KR. Psychotropic medication treatment of adolescents: results from the national comorbidity survey-adolescent supplement. J Am Acad Child Adolesc Psychiatry 2013; 52: 378-388. doi:10.1016/j.jaac.2012.12.006.
19. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte-Verlag: Köln, 2007.
20. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-1696. doi:10.1001/jama.297.15.1683.
21. Kragh-Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh) 1981; 48: 53-60. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6939299 (accessed 5 March 2014).
22. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214. doi:10.2165/00003088-199426030-00004.
23. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2013. Springer: Berlin, Heidelberg, 2013.
24. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen, Abschlussbericht. Köln, 2013.
25. Stegmann B, Wenzel-Seifert K, Haen E. Depressive disorders in childhood and adolescence-an analysis of KinderAGATE 2010. Z Kinder Jugendpsychiatr Psychother 2013; 41: 109-119. doi:10.1024/1422-4917/a000218.
26. Bramesfeld A, Grobe T, Schwartz FW. Prevalence of depression diagnosis and prescription of antidepressants in East and West Germany: an analysis of health insurance data. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 329-335. doi:10.1007/s00127-009-0067-8.
27. Hoffmann F, Bachmann C. Unterschiede in den soziodemographischen Merkmalen, der Gesundheit und Inanspruchnahme bei Kindern und Jugendlichen nach ihrer Krankenkassenzugehörigkeit. Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 2014; 57: 455-463. doi: 10.1007/s00103-013-1916-x.